Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,260,437
  • Shares Outstanding, K 93,049
  • Annual Sales, $ 1,040 K
  • Annual Income, $ -298,410 K
  • EBIT $ -307 M
  • EBITDA $ -319 M
  • 60-Month Beta 0.58
  • Price/Sales 3,170.29
  • Price/Cash Flow N/A
  • Price/Book 2.48

Options Overview Details

View History
  • Implied Volatility 61.23% ( +2.75%)
  • Historical Volatility 50.69%
  • IV Percentile 81%
  • IV Rank 49.89%
  • IV High 88.58% on 03/15/24
  • IV Low 34.00% on 09/24/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 4,662
  • Open Int (30-Day) 4,087

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.97
  • Number of Estimates 7
  • High Estimate -0.80
  • Low Estimate -1.08
  • Prior Year -0.93
  • Growth Rate Est. (year over year) -4.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.84 +8.26%
on 02/25/25
37.67 -8.51%
on 02/24/25
-0.74 (-2.10%)
since 02/14/25
3-Month
31.84 +8.26%
on 02/25/25
56.15 -38.61%
on 12/17/24
-19.19 (-35.76%)
since 12/13/24
52-Week
31.84 +8.26%
on 02/25/25
62.53 -44.87%
on 11/14/24
-3.74 (-9.79%)
since 03/14/24

Most Recent Stories

More News
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 34.47 (-1.63%)
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

CRNX : 34.47 (-1.63%)
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

CRNX : 34.47 (-1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly,...

See More

Key Turning Points

3rd Resistance Point 36.54
2nd Resistance Point 36.08
1st Resistance Point 35.28
Last Price 34.47
1st Support Level 34.02
2nd Support Level 33.56
3rd Support Level 32.76

See More

52-Week High 62.53
Fibonacci 61.8% 50.81
Fibonacci 50% 47.18
Fibonacci 38.2% 43.56
Last Price 34.47
52-Week Low 31.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar